Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBANASDAQ:CRNXNASDAQ:MRUSNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.92+2.1%$2.20$0.80▼$2.97$766.90M0.882.91 million shs3.96 million shsCRNXCrinetics Pharmaceuticals$29.50-0.9%$31.19$24.10▼$62.53$2.76B0.31854,726 shs1.41 million shsMRUSMerus$50.80-7.9%$42.88$33.19▼$61.28$3.52B0.94741,468 shs2.72 million shsSRRKScholar Rock$30.47+1.6%$30.69$6.76▼$46.98$2.89B0.371.27 million shs1.57 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%+2.14%+20.17%+57.14%+160.00%CRNXCrinetics Pharmaceuticals0.00%-3.84%-8.12%-7.86%-37.31%MRUSMerus0.00%+33.32%+26.55%+24.19%-8.08%SRRKScholar Rock0.00%-0.53%-8.56%-17.47%+181.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.2896 of 5 stars4.62.00.04.03.50.00.6CRNXCrinetics Pharmaceuticals3.6943 of 5 stars3.51.00.03.73.52.50.0MRUSMerus3.0653 of 5 stars4.63.00.00.02.61.70.0SRRKScholar Rock4.0196 of 5 stars3.50.00.04.43.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.63126.88% UpsideCRNXCrinetics Pharmaceuticals 2.91Moderate Buy$74.56152.73% UpsideMRUSMerus 3.13Buy$86.0069.29% UpsideSRRKScholar Rock 3.00Buy$42.6740.03% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, CRNX, SRRK, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.004/28/2025AKBAAkebia TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025AKBAAkebia TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.004/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/9/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$83.00 ➝ $83.004/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/1/2025AKBAAkebia TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.003/28/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$184.91M4.15N/AN/A($0.16) per share-18.25CRNXCrinetics Pharmaceuticals$760K3,634.28N/AN/A$8.07 per share3.66MRUSMerus$54.73M64.24N/AN/A$6.17 per share8.23SRRKScholar Rock$33.19M87.16N/AN/A$3.12 per share9.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.21N/AN/AN/A-27.07%N/A-20.57%8/14/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$214.53M-$3.82N/AN/AN/AN/A-36.12%-31.89%8/6/2025 (Estimated)MRUSMerus-$154.94M-$4.08N/AN/AN/A-680.61%-38.89%-31.16%7/30/2025 (Estimated)SRRKScholar Rock-$165.79M-$2.53N/AN/AN/AN/A-145.60%-91.83%8/14/2025 (Estimated)Latest AKBA, CRNX, SRRK, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million3/13/2025Q4 2024AKBAAkebia Therapeutics-$0.05-$0.10-$0.05-$0.10$37.36 million$46.50 million2/27/2025Q4 2024CRNXCrinetics Pharmaceuticals-$0.92-$0.88+$0.04-$0.88$0.73 millionN/A2/27/2025Q4 2024MRUSMerus-$0.89-$0.41+$0.48-$0.41$10.57 million$9.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.521.21CRNXCrinetics PharmaceuticalsN/A16.3916.38MRUSMerusN/A8.328.32SRRKScholar Rock0.633.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CRNXCrinetics Pharmaceuticals98.51%MRUSMerus96.14%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%CRNXCrinetics Pharmaceuticals4.60%MRUSMerus4.57%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million209.24 millionOptionableCRNXCrinetics Pharmaceuticals21093.63 million87.17 millionOptionableMRUSMerus3769.21 million65.34 millionOptionableSRRKScholar Rock14094.95 million75.64 millionOptionableAKBA, CRNX, SRRK, and MRUS HeadlinesRecent News About These CompaniesScholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by Voloridge Investment Management LLCMay 27 at 4:46 AM | marketbeat.comBank of America Corp DE Trims Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 27 at 3:15 AM | marketbeat.comTwo Sigma Advisers LP Sells 330,600 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 25 at 4:33 AM | marketbeat.comTwo Sigma Investments LP Sells 221,365 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 25 at 4:23 AM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Acquired by ProShare Advisors LLCMay 25 at 4:03 AM | marketbeat.comBNP Paribas Financial Markets Sells 13,394 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 23, 2025 | marketbeat.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Purchases New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 22, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by Woodline Partners LPMay 22, 2025 | marketbeat.comSoleus Capital Management L.P. Invests $7.24 Million in Scholar Rock Holding Co. (NASDAQ:SRRK)May 21, 2025 | marketbeat.comRafferty Asset Management LLC Sells 37,595 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 21, 2025 | marketbeat.comPolar Asset Management Partners Inc. Trims Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)May 20, 2025 | marketbeat.comDimensional Fund Advisors LP Lowers Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 20, 2025 | marketbeat.comHC Wainwright Boosts Earnings Estimates for Scholar RockMay 20, 2025 | marketbeat.comWedbush Forecasts Scholar Rock's Q2 Earnings (NASDAQ:SRRK)May 20, 2025 | americanbankingnews.comWhat is Wedbush's Estimate for Scholar Rock Q2 Earnings?May 20, 2025 | marketbeat.comDeutsche Bank AG Has $8 Million Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)May 19, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Stock Holdings Lessened by Sphera Funds Management LTD.May 18, 2025 | marketbeat.comWhat is Wedbush's Forecast for Scholar Rock FY2029 Earnings?May 18, 2025 | americanbankingnews.comPolar Capital Holdings Plc Reduces Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 17, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Acquired by Janus Henderson Group PLCMay 17, 2025 | marketbeat.comScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, CRNX, SRRK, and MRUS Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$2.92 +0.06 (+2.10%) Closing price 04:00 PM EasternExtended Trading$2.90 -0.02 (-0.68%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Crinetics Pharmaceuticals NASDAQ:CRNX$29.50 -0.26 (-0.87%) Closing price 04:00 PM EasternExtended Trading$29.50 0.00 (0.00%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Merus NASDAQ:MRUS$50.80 -4.34 (-7.87%) Closing price 04:00 PM EasternExtended Trading$50.88 +0.09 (+0.17%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Scholar Rock NASDAQ:SRRK$30.47 +0.47 (+1.57%) Closing price 04:00 PM EasternExtended Trading$30.50 +0.04 (+0.11%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
